Sun Pharmaceutical Industries Ltd. 524715 shares inched down 0.16% to 1,739.95 Indian rupees Monday, on what proved to be an all-around grim trading session for the stock market, with the BSE SENSEX ...

The pharmaceutical business Sun Pharma held the meeting on January 31, 2025. The company announced the record date and ...

A recap of the most heavily shorted stocks on the ASX and those experiencing significant changes to short interest over the ...

Sun Pharma's Q3FY25 net profit rose 15% YoY to ₹2,903 crore, driven by strong domestic and global specialty sales. Revenue ...

Analysts see support at 23,200, and a break below this level could trigger a decline towards 23,000. On the other hand, a decisive move above 23,300 might push the index towards 23,500.

The Nifty50 index is expected to have established a short-term bottom near the 22,800 mark, with immediate support at 22,780.

The market may continue to consolidate further, taking cues from Union Budget, FOMC meeting, quarterly earnings, US GDP ...

Wesfarmers ( ASX: WES) – Shares ticked 2.3% higher after Goldman Sachs upgraded the stock from Neutral to Buy, and lifted their target price to $78.70 (from $69.50). The report highlighted new growth ...

The government can think of implementing measures that not only boost demand but also are in sync with broader economic ...

Hydrochloride for Injection, USP in two vial sizes: 25 mg/1 mL and 50 mg/2 mL, further broadening PCC's increasing portfolio ...

(Image: Freepik) Stocks in Focus: GIFT Nifty was trading 65 points or 0.28% lower ... the same period of the previous financial year. Sun Pharmaceutical has announced that its subsidiary, Taro ...

Drugmaker Sun Pharmaceutical Industries has entered into a definitive agreement to acquire 100% stake in Antibe Therapeutics Inc., an Ontario, Canada incorporated clinical-stage biotechnological ...